Please wait while the formulary information is being retrieved.
Drug overview for FUSILEV (levoleucovorin calcium):
Generic name: levoleucovorin calcium (LEE-voe-LOO-koe-VOR-in)
Drug class: Folic Acid
Therapeutic class: Antineoplastics
Levoleucovorin calcium, the levorotatory (l) isomer of racemic d,l-leucovorin, is one of several active, chemically reduced derivatives of folic acid.
No enhanced Uses information available for this drug.
Generic name: levoleucovorin calcium (LEE-voe-LOO-koe-VOR-in)
Drug class: Folic Acid
Therapeutic class: Antineoplastics
Levoleucovorin calcium, the levorotatory (l) isomer of racemic d,l-leucovorin, is one of several active, chemically reduced derivatives of folic acid.
No enhanced Uses information available for this drug.
DRUG IMAGES
FUSILEV I.V. 50 MG VIAL
The following indications for FUSILEV (levoleucovorin calcium) have been approved by the FDA:
Indications:
Adjunct to fluorouracil treatment of colorectal cancer
Bone marrow suppression due to folic acid antagonism
Methotrexate toxicity
Pyrimethamine toxicity
Sulfadiazine toxicity
Trimethoprim toxicity
Trimetrexate toxicity
Professional Synonyms:
Adjunct to fluorouracil treatment of adenocarcinoma of colon and rectum
Adjuvant therapy with 5-FU for colorectal cancer
Bone marrow depression due to folic acid antagonism
Bone marrow hypoplasia due to folic acid antagonism
Hypoplasia of bone marrow due to folic acid antagonism
MTX toxicity
Myelosuppression due to folic acid antagonism
TMP toxicity
Indications:
Adjunct to fluorouracil treatment of colorectal cancer
Bone marrow suppression due to folic acid antagonism
Methotrexate toxicity
Pyrimethamine toxicity
Sulfadiazine toxicity
Trimethoprim toxicity
Trimetrexate toxicity
Professional Synonyms:
Adjunct to fluorouracil treatment of adenocarcinoma of colon and rectum
Adjuvant therapy with 5-FU for colorectal cancer
Bone marrow depression due to folic acid antagonism
Bone marrow hypoplasia due to folic acid antagonism
Hypoplasia of bone marrow due to folic acid antagonism
MTX toxicity
Myelosuppression due to folic acid antagonism
TMP toxicity
The following dosing information is available for FUSILEV (levoleucovorin calcium):
Levoleucovorin is commercially available as the calcium pentahydrate; dosage of the drug is expressed in terms of levoleucovorin (i.e., 64 mg of levoleucovorin calcium pentahydrate is equivalent to 50 mg of levoleucovorin).
Levoleucovorin is dosed at one-half the usual dosage of racemic leucovorin. (See Description.)The manufacturer makes no specific recommendations regarding dosage in pediatric patients; however, safety and efficacy of levoleucovorin have been evaluated in 16 patients 6-21 years of age. (See Uses: Toxicity Associated with Folic Acid Antagonists.)
Dosage recommendations for levoleucovorin are based on a methotrexate dosage of 12 g/m2 administered by IV infusion over 4 hours; the prescribing information for methotrexate should be consulted for additional information. Dosage and duration of levoleucovorin rescue therapy should be adjusted based on the elimination pattern of methotrexate and the patient's renal function (see Table 1).
Serum creatinine and methotrexate concentrations should be monitored at least once daily. Levoleucovorin therapy should be continued, and adequate hydration and urinary alkalinization (pH of 7 or greater) maintained, until serum methotrexate concentration declines to less than 0.05 micromolar (5 x 10-8M).
Patients who experience delayed early methotrexate elimination are likely to develop reversible renal failure; therefore, fluid and electrolyte status also should be closely monitored in such patients until serum methotrexate concentration declines to less than 0.05 micromolar (5 x 10-8M) and renal failure has resolved.
Table 1. Guidelines for Levoleucovorin Dosage Adjustment in Patients with Normal or Delayed Methotrexate Elimination
Clinical Situation Serum Methotrexate Levoleucovorin Dosage Concentration and Monitoring Normal methotrexate Approximately 10 7.5 mg (approximately 5 elimination micromolar (10-5M) at 24 mg/m2) IV every 6 hours hours, 1 micromolar for 60 hours (10 doses), (10-6M) at 48 hours, and starting at 24 hours less than 0.2 micromolar after initiation of (2 x 10-7M) at 72 hours methotrexate infusion after methotrexate administration Delayed late Greater than 0.2
Continue levoleucovorin methotrexate elimination micromolar (2 x 10-7M) 7.5 mg IV every 6 hours at 72 hours and greater until methotrexate than 0.05 micromolar (5 concentration declines x 10-8M) at 96 hours to less than 0.05
after methotrexate micromolar (5 x 10-8M) administration Delayed early 50 micromolar (5 x 75 mg IV every 3 hours methotrexate elimination 10-5M) or greater at 24 until methotrexate and/or evidence of acute hours or 5 micromolar (5 concentration declines renal injury x 10-6M) or greater at to less than 1 48 hours after micromolar (10-6M), then methotrexate 7.5 mg IV every 3 hours administration, or a until methotrexate 100% or greater increase concentration declines in serum creatinine to less than 0.05 concentration at 24 micromolar (5 x 10-8M) hours after methotrexate administration (e.g., an increase from 0.5 to 1 mg/dL or more)
The possibility that the patient is receiving other drugs that interact with methotrexate (e.g., by decreasing methotrexate elimination, binding to serum albumin) should always be considered when laboratory abnormalities or clinical toxicities are observed.
In patients with mild abnormalities in methotrexate elimination or renal function who experience clinically important toxicity, levoleucovorin rescue should be extended for an additional 24 hours (i.e., 14 doses over 84 hours) for subsequent methotrexate courses.
Levoleucovorin rescue should begin as soon as possible following unintentional overdosage and within 24 hours of methotrexate administration if delayed elimination is detected; delayed administration of levoleucovorin may reduce its effectiveness in counteracting toxicity associated with folic acid antagonists.
The usual levoleucovorin dosage for management of methotrexate overdosage is 7.5 mg (approximately 5 mg/m2) IV every 6 hours until serum methotrexate concentration declines to less than 0.01 micromolar (10-8M).
Serum creatinine and serum methotrexate concentrations should be determined at 24-hour intervals. If the 24-hour serum creatinine concentration increases 50% over baseline, the 24-hour methotrexate concentration is greater than 5 micromolar (5 x 10-6M), or the 48-hour methotrexate concentration is greater than 0.9 micromolar (9 x 10-7M), levoleucovorin dosage should be increased to 50 mg/m2 IV every 3 hours until serum methotrexate concentration declines to less than 0.01
micromolar (10-8M). Hydration (3 L daily) and urinary alkalinization with sodium bicarbonate (to maintain a urinary pH of 7 or greater) should be employed concomitantly.
Levoleucovorin is dosed at one-half the usual dosage of racemic leucovorin. (See Description.)The manufacturer makes no specific recommendations regarding dosage in pediatric patients; however, safety and efficacy of levoleucovorin have been evaluated in 16 patients 6-21 years of age. (See Uses: Toxicity Associated with Folic Acid Antagonists.)
Dosage recommendations for levoleucovorin are based on a methotrexate dosage of 12 g/m2 administered by IV infusion over 4 hours; the prescribing information for methotrexate should be consulted for additional information. Dosage and duration of levoleucovorin rescue therapy should be adjusted based on the elimination pattern of methotrexate and the patient's renal function (see Table 1).
Serum creatinine and methotrexate concentrations should be monitored at least once daily. Levoleucovorin therapy should be continued, and adequate hydration and urinary alkalinization (pH of 7 or greater) maintained, until serum methotrexate concentration declines to less than 0.05 micromolar (5 x 10-8M).
Patients who experience delayed early methotrexate elimination are likely to develop reversible renal failure; therefore, fluid and electrolyte status also should be closely monitored in such patients until serum methotrexate concentration declines to less than 0.05 micromolar (5 x 10-8M) and renal failure has resolved.
Table 1. Guidelines for Levoleucovorin Dosage Adjustment in Patients with Normal or Delayed Methotrexate Elimination
Clinical Situation Serum Methotrexate Levoleucovorin Dosage Concentration and Monitoring Normal methotrexate Approximately 10 7.5 mg (approximately 5 elimination micromolar (10-5M) at 24 mg/m2) IV every 6 hours hours, 1 micromolar for 60 hours (10 doses), (10-6M) at 48 hours, and starting at 24 hours less than 0.2 micromolar after initiation of (2 x 10-7M) at 72 hours methotrexate infusion after methotrexate administration Delayed late Greater than 0.2
Continue levoleucovorin methotrexate elimination micromolar (2 x 10-7M) 7.5 mg IV every 6 hours at 72 hours and greater until methotrexate than 0.05 micromolar (5 concentration declines x 10-8M) at 96 hours to less than 0.05
after methotrexate micromolar (5 x 10-8M) administration Delayed early 50 micromolar (5 x 75 mg IV every 3 hours methotrexate elimination 10-5M) or greater at 24 until methotrexate and/or evidence of acute hours or 5 micromolar (5 concentration declines renal injury x 10-6M) or greater at to less than 1 48 hours after micromolar (10-6M), then methotrexate 7.5 mg IV every 3 hours administration, or a until methotrexate 100% or greater increase concentration declines in serum creatinine to less than 0.05 concentration at 24 micromolar (5 x 10-8M) hours after methotrexate administration (e.g., an increase from 0.5 to 1 mg/dL or more)
The possibility that the patient is receiving other drugs that interact with methotrexate (e.g., by decreasing methotrexate elimination, binding to serum albumin) should always be considered when laboratory abnormalities or clinical toxicities are observed.
In patients with mild abnormalities in methotrexate elimination or renal function who experience clinically important toxicity, levoleucovorin rescue should be extended for an additional 24 hours (i.e., 14 doses over 84 hours) for subsequent methotrexate courses.
Levoleucovorin rescue should begin as soon as possible following unintentional overdosage and within 24 hours of methotrexate administration if delayed elimination is detected; delayed administration of levoleucovorin may reduce its effectiveness in counteracting toxicity associated with folic acid antagonists.
The usual levoleucovorin dosage for management of methotrexate overdosage is 7.5 mg (approximately 5 mg/m2) IV every 6 hours until serum methotrexate concentration declines to less than 0.01 micromolar (10-8M).
Serum creatinine and serum methotrexate concentrations should be determined at 24-hour intervals. If the 24-hour serum creatinine concentration increases 50% over baseline, the 24-hour methotrexate concentration is greater than 5 micromolar (5 x 10-6M), or the 48-hour methotrexate concentration is greater than 0.9 micromolar (9 x 10-7M), levoleucovorin dosage should be increased to 50 mg/m2 IV every 3 hours until serum methotrexate concentration declines to less than 0.01
micromolar (10-8M). Hydration (3 L daily) and urinary alkalinization with sodium bicarbonate (to maintain a urinary pH of 7 or greater) should be employed concomitantly.
No enhanced Administration information available for this drug.
No dosing information available.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| LEVOLEUCOVORIN 50 MG VIAL | Maintenance | Adults infuse 7.5 mg by intravenous route every 6 hours for 10 doses |
The following drug interaction information is available for FUSILEV (levoleucovorin calcium):
There are 0 contraindications.
There are 0 severe interactions.
There are 5 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| Hydantoins/Folic Acid; Pyrimethamine SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Unknown, but probably involves altered metabolism of the hydantoin. CLINICAL EFFECTS: May observe decreased effectiveness of hydantoin, resulting in loss of seizure control. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: If both drugs are administered, monitor both the hydantoin plasma levels as well as the seizure control of the patient. Adjust the dose of hydantoin accordingly. DISCUSSION: The effects of an interaction are not expected to occur in the majority of patients. Discontinuation of folic acid has caused phenytoin levels to increase in patients who experienced a decrease in phenytoin levels when folic acid was started. Monitor these patients for hydantoin toxicity. Signs and symptoms of hydantoin toxicity include ataxia, nystagmus and involuntary movements. |
CEREBYX, DILANTIN, DILANTIN-125, FOSPHENYTOIN SODIUM, PHENYTEK, PHENYTOIN, PHENYTOIN SODIUM, PHENYTOIN SODIUM EXTENDED |
| Levoleucovorin; Leucovorin/Glucarpidase SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Glucarpidase hydrolyzes the carboxyl-terminal glutamate residue from folates such as leucovorin, rendering them inactive.(1) CLINICAL EFFECTS: A leucovorin dose given near the time of glucarpidase administration may not be effective. PREDISPOSING FACTORS: Leucovorin dose given within two hours of glucarpidase administration. PATIENT MANAGEMENT: The combination of glucarpidase and leucovorin are used to treat toxic concentrations of methotrexate. Patients with potentially life threatening methotrexate serum levels or toxicity must receive both drugs. However, in addition to inactivating methotrexate, glucarpidase also inactivates leucovorin. To help decrease leucovorin inactivation, stagger leucovorin administration so it is not given within two hours of glucarpidase dose. Continue leucovorin treatment based upon pre-glucarpidase methotrexate blood levels.(1) Note that depending upon the laboratory assay used, glucarpidase administration may cause erroneous methotrexate measurements for 48 hours post dose.(1) DISCUSSION: In a study of cancer patients treated with a high dose methotrexate and leucovorin rescue regimen, glucarpidase given two hours before leucovorin reduced the area-under-curve (AUC) of the active leucovorin metabolite, 5-methyltetrahydrofolate, by 92 per cent.(1) |
VORAXAZE |
| Trimethoprim-Sulfamethoxazole/Leucovorin SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Leucovorin may protect Pneumocystis jirovecii from the effects of trimethoprim-sulfamethoxazole by providing a source of folate.(1,2) CLINICAL EFFECTS: Concurrent use of leucovorin in patients undergoing prophylaxis against or being treated for Pneumocystis jiroveci pneumonia (formerly called Pneumocystic carinii) with trimethoprim-sulfamethoxazole has been associated with treatment failure and increased mortality.(1-4) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The concurrent use of leucovorin and trimethoprim-sulfamethoxazole should be avoided in patients undergoing prophylaxis against or being treated for Pneumocystis jiroveci (formerly carinii) pneumonia.(1-4) Leucovorin is an effective treatment for trimethoprim-sulfamethoxazole induced bone marrow suppression.(3) DISCUSSION: In a prospective, double-blind study in 92 AIDS patients with Pneumocystis jiroveci (formerly carinii) pneumonia, concurrent use of leucovorin with trimethoprim-sulfamethoxazole resulted in an increase in treatment failure (15% versus 0) and death (11% versus 0). Leucovorin was also associated with a shorter time to therapeutic failure. Patients receiving leucovorin did have a lower incidence of neutropenia; however, there was no difference in the time to occurrence of neutropenia.(4) In a study in 12 AIDS/ARC patients, leucovorin had no effect on trimethoprim-sulfamethoxazole induced cytopenia.(5) In a study in HIV patients with no history of Pneumocystis jiroveci pneumonia, administration of leucovorin had no effect on patient tolerance to trimethoprim-sulfamethoxazole.(6) In a case report, two renal transplant patients with Pneumocystis jiroveci pneumonia failed to respond to treatment with trimethoprim-sulfamethoxazole until concurrent leucovorin was discontinued.(1) In a case report, an AIDS patient developed Pneumocystis jiroveci pneumonia despite a regimen of concurrent trimethoprim-sulfamethoxazole and leucovorin.(2) |
BACTRIM, BACTRIM DS, SULFAMETHOXAZOLE-TRIMETHOPRIM, SULFATRIM |
| 5-Fluorouracil/Leucovorin SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Leucovorin has been shown to enhance both the therapeutic and toxic effects of fluoropyrimidines, such as 5-fluorouracil(5-FU).(1) CLINICAL EFFECTS: Leucovorin, when used concurrently with 5-FU, has been shown to increase side effects of 5-FU.(1) PREDISPOSING FACTORS: Patients who are intermediate or poor dihydropyrimidine dehydrogenase (DPYD) metabolizers have diminished or no DPYD function. Since DPYD is the rate-limiting enzyme involved in fluoropyrimidine metabolism, these patients may be more susceptible to the effects of this interaction.(3) PATIENT MANAGEMENT: When leucovorin is added to 5-FU therapy, the dose of 5-FU must be reduced from that of the normally administered dose. Patients should be closely monitored for appearance and severity of side effects to determine whether it is appropriate to alter the dose of 5-FU.(1) DISCUSSION: A retrospective study reviewed all patients over the age of 18 years treated with combination fluorouracil and leucovorin either as adjuvant or palliative treatment. A total of 122 patients (60% male) were included in the study. Ninety-four patients received fluorouracil (425 mg/m2, IV) and leucovorin (20 mg/m2, IV) daily for five days and repeated every four weeks. Twenty-eight patients received fluorouracil (400 mg/m2, IV) and leucovorin (80 mg/m2, IV) once per week for six weeks of an eight week course. All patients were treated for up to six months. Forty-eight patients (39%) experienced toxicity including fatigue (21%), mucositis (17%), diarrhea (11%), and nausea (11%).(2) A study involving 35 patients evaluated a combination of cisplatin (20 mg/m2) on Day 1 through Day 3, leucovorin (200 mg/m2) on Day 1 through Day 5, and 5-fluorouracil (500 mg/m2) on Day 1 through Day 5. If patients tolerated the low dose of 5-fluorouracil, the dose was increased to a maximum of 750 mg/m2/day during the remaining courses. Grade I mucositis occurred in three patients, Grade II in 16 patients, and Grade III in 13 patients. The dose of 5-fluorouracil was decreased in patients with Grade II and Grade III mucositis, which helped to decrease symptoms.(3) A randomized trial in advanced colorectal carcinoma patients compared fluorouracil (500 mg/m2 on Days 1-5) every four weeks with escalation as tolerated with high-dose leucovorin (500mg/m2) with fluorouracil (600 mg/m2) given weekly for six weeks with a two-week rest period and with low-dose leucovorin (25 mg/m2) with fluorouracil (600 mg/m2) given weekly for six weeks with a two-week rest period. Severe or worse diarrhea was reported in 25% and 13% of patients receiving high-dose leucovorin and low-dose leucovorin with fluorouracil, respectively. Nine elderly patients experienced fatal toxicity during the initial treatment cycle with combination therapy.(4) A study in five patients with metastatic colorectal carcinoma examined the effects of high dose leucovorin (500 mg/m2) on fluorouracil pharmacokinetics. Subjects received a single dose of fluorouracil (600 mg/m2) with leucovorin and, one week later, without leucovorin. With concurrent leucovorin, the time of distribution of fluorouracil increased 44% (p<0.0005) and fluorouracil volume of distribution increased 84% (p<0.03). There were no changes in fluorouracil plasma clearance or AUC. Although fluorouracil anabolite levels were lower at two minutes and five minutes post-dose when administered following leucovorin, levels were similar thereafter.(5) |
ADRUCIL, CAPECITABINE, FLUOROURACIL, XELODA |
| Pafolacianine/Folic Acid SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Folate, folic acid, and folate-containing supplements may reduce binding of pafolacianine to folate receptors expressed on ovarian cancer cells. CLINICAL EFFECTS: Folate, folic acid, and folate-containing supplements could reduce the detection of malignant lesions with pafolacianine. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Avoid administration of folate, folic acid, or folate-containing supplements within 48 hours before administration of pafolacianine. DISCUSSION: Folate, folic acid, and folate-containing supplements may reduce binding of pafolacianine to folate receptors expressed on cancer cells, which could result in reduced detection of malignant lesions with pafolacianine. |
CYTALUX |
The following contraindication information is available for FUSILEV (levoleucovorin calcium):
Drug contraindication overview.
Pernicious anemia or other megaloblastic anemias secondary to lack of vitamin B12; such use may obscure the diagnosis of pernicious anemia by alleviating hematologic manifestations while allowing neurologic complications to progress. Hypersensitivity to folic acid or folinic acid.
Pernicious anemia or other megaloblastic anemias secondary to lack of vitamin B12; such use may obscure the diagnosis of pernicious anemia by alleviating hematologic manifestations while allowing neurologic complications to progress. Hypersensitivity to folic acid or folinic acid.
There are 0 contraindications.
There are 0 severe contraindications.
There are 1 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Colitis |
The following adverse reaction information is available for FUSILEV (levoleucovorin calcium):
Adverse reaction overview.
Adverse effects reported in more than 15% of patients receiving levoleucovorin rescue following high-dose methotrexate therapy include vomiting, stomatitis, and nausea. Less frequently reported adverse effects, occurring in less than 10% of patients, include diarrhea, dyspepsia, typhlitis, dyspnea, dermatitis, confusion, neuropathy, abnormal renal function, and taste perversion. Adverse effects reported in more than 50% of patients with advanced-stage colorectal cancer receiving levoleucovorin in combination with fluorouracil include diarrhea, nausea, and stomatitis.
Other frequently reported adverse effects, occurring in 20-40% of patients, include vomiting, asthenia/fatigue/malaise, anorexia/decreased appetite, dermatitis, and alopecia. The incidence of adverse effects is similar to that reported in patients receiving an equipotent dosage of racemic leucovorin in combination with fluorouracil.
Adverse effects reported in more than 15% of patients receiving levoleucovorin rescue following high-dose methotrexate therapy include vomiting, stomatitis, and nausea. Less frequently reported adverse effects, occurring in less than 10% of patients, include diarrhea, dyspepsia, typhlitis, dyspnea, dermatitis, confusion, neuropathy, abnormal renal function, and taste perversion. Adverse effects reported in more than 50% of patients with advanced-stage colorectal cancer receiving levoleucovorin in combination with fluorouracil include diarrhea, nausea, and stomatitis.
Other frequently reported adverse effects, occurring in 20-40% of patients, include vomiting, asthenia/fatigue/malaise, anorexia/decreased appetite, dermatitis, and alopecia. The incidence of adverse effects is similar to that reported in patients receiving an equipotent dosage of racemic leucovorin in combination with fluorouracil.
There are 7 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. | None. |
| Rare/Very Rare |
|---|
|
Anaphylaxis Dyspnea Hypersensitivity drug reaction Seizure disorder Stevens-johnson syndrome Toxic epidermal necrolysis Urticaria |
There are 4 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. | None. |
| Rare/Very Rare |
|---|
|
Chills Pruritus of skin Skin rash Syncope |
The following precautions are available for FUSILEV (levoleucovorin calcium):
Safety and efficacy of levoleucovorin have been evaluated in 16 patients 6-21 years of age. (See Uses: Toxicity Associated with Folic Acid Antagonists.) The manufacturer makes no specific recommendations regarding use in pediatric patients.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Category C. (See Users Guide.)
It is not known whether levoleucovorin is distributed into milk; because of the potential for serious adverse reactions to levoleucovorin in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman.
Clinical studies of levoleucovorin in the treatment of osteosarcoma did not include patients 65 years of age and older to determine whether geriatric patients respond differently than younger patients. In a clinical trial evaluating levoleucovorin in combination with fluorouracil for the treatment of advanced-stage colorectal cancer, adverse reactions were consistent with known toxicities of fluorouracil; no overall differences in adverse effects were observed between geriatric patients (65 years of age or older) and younger adults. However, deaths from severe enterocolitis, diarrhea, and dehydration have been reported in geriatric patients receiving weekly racemic leucovorin concomitantly with fluorouracil. (See Cautions: Precautions and Contraindications, in Leucovorin Calcium 92:12.)
The following prioritized warning is available for FUSILEV (levoleucovorin calcium):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for FUSILEV (levoleucovorin calcium)'s list of indications:
| Adjunct to fluorouracil treatment of colorectal cancer | |
| C18 | Malignant neoplasm of colon |
| C18.0 | Malignant neoplasm of cecum |
| C18.1 | Malignant neoplasm of appendix |
| C18.2 | Malignant neoplasm of ascending colon |
| C18.3 | Malignant neoplasm of hepatic flexure |
| C18.4 | Malignant neoplasm of transverse colon |
| C18.5 | Malignant neoplasm of splenic flexure |
| C18.6 | Malignant neoplasm of descending colon |
| C18.7 | Malignant neoplasm of sigmoid colon |
| C18.8 | Malignant neoplasm of overlapping sites of colon |
| C18.9 | Malignant neoplasm of colon, unspecified |
| C19 | Malignant neoplasm of rectosigmoid junction |
| C20 | Malignant neoplasm of rectum |
Formulary Reference Tool